Overview

A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

Status:
Completed

Trial end date:
2019-08-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ixazomib plus lenalidomide and dexamethasone in Japanese participants with relapsed and/or refractory multiple myeloma (RRMM).

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Glycine
Ixazomib
Lenalidomide
Thalidomide